Miguel Ángel Labrador-Espinosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miguel Ángel Labrador-Espinosa has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Michel J. Grothe
CIEN Foundation, Reina Sofia Alzheimer Center, ISCIII, Madrid, Madrid, Spain
4 shared publications - Pablo Mir
Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
4 shared publications - Astrid Adarmes-Gómez
Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, 41013, Spain
3 shared publications - Daniel Macías-García
Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, 41013, Spain
3 shared publications Fátima Carrillo
Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, 41013, Spain
3 shared publications- Jesús Silva-Rodríguez
Reina Sofia Alzheimer Centre, CIEN Foundation, ISCIII, Madrid, Spain
3 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (12) , 7391-7406
Semiquantitative [¹²³I]FP-CIT SPECT metrics combined with machine learning improve clinical differentiation of Parkinson’s disease and atypical parkinsonian syndrome
Purpose: To evaluate whether semiquantitative striatal [¹²³I]FP-CIT SPECT-derived metrics improve clinical differentiation of degenerative parkinsonism using an integrated machine learning approach. Methods: This cross-sectional study included 487 patients with Parkinson’s disease (PD) and 219 with atypical parkinsonisms (APS), classified as progressive supranuclear palsy (PSP, n = 127), multiple system atrophy parkinsonian type (MSA-P, n = 37), multiple system atrophy cerebellar type (MSA-C, n = 12), and corticobasal degeneration (CBD, n = 43). All participants underwent a [¹²³I]FP-CIT SPECT. Striatal [¹²³I]FP-CIT uptake was quantified using anatomical (caudate, putamen, ventral striatum) and functional (limbic, executive, sensorimotor) parcellations to calculate specific binding ratios, asymmetry indices, and inter-regional ratios. Discriminative performance of each metric was evaluated using receiver operating characteristic (ROC) curves analyses. A random forest classifier integrating all semiquantitative metrics was trained and validated, enabling data-driven identification diagnostic pathways. Results: Caudate-to-putamen and sensorimotor-to-limbic inter-regional ratios showed the strongest discriminative performance (AUC up to 0.95) for differentiating PD from APS. The random forest achieved a 64% overall accuracy with high per-class specificities (> 84%) and revealed two diagnostic pathways. A lower caudate-to-posterior putamen ratio, primarily grouped PSP, CBD and MSA-C, where lower contralateral sensorimotor uptake pointing to PSP while higher values and ipsilateral caudate uptake subregion further distinguishing CBD from MSA-C. A higher caudate-to-posterior putamen ratio, included PD and MSA-P, where lower ipsilateral caudate uptake together with a higher sensorimotor-to-cognitive ratio mainly differentiate both groups. Conclusions: Integrating anatomical and functional [¹²³I]FP-CIT SPECT metrics within a machine learning framework enhances the clinical differentiation of degenerative parkinsonisms and supports [¹²³I]FP-CIT SPECT as a robust in vivo disease biomarker.
- 3 July 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (12) , 7391-7406
Open AccessSemiquantitative [¹²³I]FP-CIT SPECT metrics combined with machine learning improve clinical differentiation of Parkinson’s disease and atypical parkinsonian syndrome
Purpose: To evaluate whether semiquantitative striatal [¹²³I]FP-CIT SPECT-derived metrics improve clinical differentiation of degenerative parkinsonism using an integrated machine learning approach. Methods: This cross-sectional study included 487 patients with Parkinson’s disease (PD) and 219 with atypical parkinsonisms (APS), classified as progressive supranuclear palsy (PSP, n = 127), multiple system atrophy parkinsonian type (MSA-P, n = 37), multiple system atrophy cerebellar type (MSA-C, n = 12), and corticobasal degeneration (CBD, n = 43). All participants underwent a [¹²³I]FP-CIT SPECT. Striatal [¹²³I]FP-CIT uptake was quantified using anatomical (caudate, putamen, ventral striatum) and functional (limbic, executive, sensorimotor) parcellations to calculate specific binding ratios, asymmetry indices, and inter-regional ratios. Discriminative performance of each metric was evaluated using receiver operating characteristic (ROC) curves analyses. A random forest classifier integrating all semiquantitative metrics was trained and validated, enabling data-driven identification diagnostic pathways. Results: Caudate-to-putamen and sensorimotor-to-limbic inter-regional ratios showed the strongest discriminative performance (AUC up to 0.95) for differentiating PD from APS. The random forest achieved a 64% overall accuracy with high per-class specificities (> 84%) and revealed two diagnostic pathways. A lower caudate-to-posterior putamen ratio, primarily grouped PSP, CBD and MSA-C, where lower contralateral sensorimotor uptake pointing to PSP while higher values and ipsilateral caudate uptake subregion further distinguishing CBD from MSA-C. A higher caudate-to-posterior putamen ratio, included PD and MSA-P, where lower ipsilateral caudate uptake together with a higher sensorimotor-to-cognitive ratio mainly differentiate both groups. Conclusions: Integrating anatomical and functional [¹²³I]FP-CIT SPECT metrics within a machine learning framework enhances the clinical differentiation of degenerative parkinsonisms and supports [¹²³I]FP-CIT SPECT as a robust in vivo disease biomarker.
- 5 December 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (6) , 2372-2380
Cortical hypometabolism in Parkinson’s disease is linked to cholinergic basal forebrain atrophy
Cortical hypometabolism on FDG-PET is a well-established neuroimaging biomarker of cognitive impairment in Parkinson’s disease (PD), but its pathophysiologic origins are incompletely understood. Cholinergic basal forebrain (cBF) degeneration is a prominent pathological feature of PD-related cognitive impairment and may contribute to cortical hypometabolism through cholinergic denervation of cortical projection areas. Here, we investigated in-vivo associations between subregional cBF volumes on 3T-MRI, cortical hypometabolism on [18F]FDG-PET, and cognitive deficits in a cohort of 95 PD participants with varying degrees of cognitive impairment. We further assessed the spatial correspondence of the cortical pattern of cBF-associated hypometabolism with the pattern of cholinergic denervation in PD as assessed by [18F]FEOBV-PET imaging of presynaptic cholinergic terminal density in a second cohort. Lower volume of the cortically-projecting posterior cBF, but not of the anterior cBF, was significantly associated with extensive neocortical hypometabolism [p(FDR) < 0.05], which mediated the association between cBF atrophy and cognitive impairment (mediated proportion: 43%, p < 0.001). In combined models, posterior cBF atrophy explained more variance in cortical hypometabolism (R2 = 0.26, p < 0.001) than local atrophy in the cortical areas themselves (R2 = 0.16, p = 0.01). Topographic correspondence analysis with the [18F]FEOBV-PET pattern revealed that cortical areas showing most pronounced cBF-associated hypometabolism correspond to those showing most severe cholinergic denervation in PD (Spearman’s ρ = 0.57, p < 0.001). In conclusion, posterior cBF atrophy in PD is selectively associated with hypometabolism in denervated cortical target areas, which mediates the effect of cBF atrophy on cognitive impairment. These data provide first-time in-vivo evidence that cholinergic degeneration represents a principle pathological correlate of cortical hypometabolism underlying cognitive impairment in PD.
- 5 December 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (6) , 2372-2380
Cortical hypometabolism in Parkinson’s disease is linked to cholinergic basal forebrain atrophy
Cortical hypometabolism on FDG-PET is a well-established neuroimaging biomarker of cognitive impairment in Parkinson’s disease (PD), but its pathophysiologic origins are incompletely understood. Cholinergic basal forebrain (cBF) degeneration is a prominent pathological feature of PD-related cognitive impairment and may contribute to cortical hypometabolism through cholinergic denervation of cortical projection areas. Here, we investigated in-vivo associations between subregional cBF volumes on 3T-MRI, cortical hypometabolism on [18F]FDG-PET, and cognitive deficits in a cohort of 95 PD participants with varying degrees of cognitive impairment. We further assessed the spatial correspondence of the cortical pattern of cBF-associated hypometabolism with the pattern of cholinergic denervation in PD as assessed by [18F]FEOBV-PET imaging of presynaptic cholinergic terminal density in a second cohort. Lower volume of the cortically-projecting posterior cBF, but not of the anterior cBF, was significantly associated with extensive neocortical hypometabolism [p(FDR) < 0.05], which mediated the association between cBF atrophy and cognitive impairment (mediated proportion: 43%, p < 0.001). In combined models, posterior cBF atrophy explained more variance in cortical hypometabolism (R2 = 0.26, p < 0.001) than local atrophy in the cortical areas themselves (R2 = 0.16, p = 0.01). Topographic correspondence analysis with the [18F]FEOBV-PET pattern revealed that cortical areas showing most pronounced cBF-associated hypometabolism correspond to those showing most severe cholinergic denervation in PD (Spearman’s ρ = 0.57, p < 0.001). In conclusion, posterior cBF atrophy in PD is selectively associated with hypometabolism in denervated cortical target areas, which mediates the effect of cBF atrophy on cognitive impairment. These data provide first-time in-vivo evidence that cholinergic degeneration represents a principle pathological correlate of cortical hypometabolism underlying cognitive impairment in PD.
- Open Access
- 26 July 2023
- Published by Wiley in Movement Disorders
- Vol. 38 (10) , 1871-1880
Basal Forebrain Atrophy, Cortical Thinning, and Amyloid‐β Status in Parkinson's disease‐Related Cognitive Decline
Background: Degeneration of the cortically‐projecting cholinergic basal forebrain (cBF) is a well‐established pathologic correlate of cognitive decline in Parkinson's disease (PD). In Alzheimer's disease (AD) the effect of cBF degeneration on cognitive decline was found to be mediated by parallel atrophy of denervated cortical areas.Objectives: To examine whether the association between cBF degeneration and cognitive decline in PD is mediated by parallel atrophy of cortical areas and whether these associations depend on the presence of comorbid AD pathology.Methods: We studied 162 de novo PD patients who underwent serial 3 T magnetic resonance imaging scanning (follow‐up: 2.33 ± 1.46 years) within the Parkinson's Progression Markers Initiative. cBF volume and regional cortical thickness were automatically calculated using established procedures. Individual slopes of structural brain changes and cognitive decline were estimated using linear‐mixed models. Associations between longitudinal cBF degeneration, regional cortical thinning, and cognitive decline were assessed using regression analyses and mediation effects were assessed using nonparametric bootstrap. Complementary analyses assessed the effect of amyloid‐β biomarker positivity on these associations.Results: After controlling for global brain atrophy, longitudinal cBF degeneration was highly correlated with faster cortical thinning (PFDR < 0.05), and thinning in cBF‐associated cortical areas mediated the association between cBF degeneration and cognitive decline (rcBF‐MoCA = 0.30, P < 0.001). Interestingly, both longitudinal cBF degeneration and its association with cortical thinning were largely independent of amyloid‐β status.Conclusions: cBF degeneration in PD is linked to parallel thinning of cortical target areas, which mediate the effect on cognitive decline. These associations are independent of amyloid‐β status, indicating that they reflect proper features of PD pathophysiology. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 26 July 2023
- Published by Wiley in Movement Disorders
- Vol. 38 (10) , 1871-1880
Open AccessBasal Forebrain Atrophy, Cortical Thinning, and Amyloid‐β Status in Parkinson's disease‐Related Cognitive Decline
Background: Degeneration of the cortically‐projecting cholinergic basal forebrain (cBF) is a well‐established pathologic correlate of cognitive decline in Parkinson's disease (PD). In Alzheimer's disease (AD) the effect of cBF degeneration on cognitive decline was found to be mediated by parallel atrophy of denervated cortical areas.Objectives: To examine whether the association between cBF degeneration and cognitive decline in PD is mediated by parallel atrophy of cortical areas and whether these associations depend on the presence of comorbid AD pathology.Methods: We studied 162 de novo PD patients who underwent serial 3 T magnetic resonance imaging scanning (follow‐up: 2.33 ± 1.46 years) within the Parkinson's Progression Markers Initiative. cBF volume and regional cortical thickness were automatically calculated using established procedures. Individual slopes of structural brain changes and cognitive decline were estimated using linear‐mixed models. Associations between longitudinal cBF degeneration, regional cortical thinning, and cognitive decline were assessed using regression analyses and mediation effects were assessed using nonparametric bootstrap. Complementary analyses assessed the effect of amyloid‐β biomarker positivity on these associations.Results: After controlling for global brain atrophy, longitudinal cBF degeneration was highly correlated with faster cortical thinning (PFDR < 0.05), and thinning in cBF‐associated cortical areas mediated the association between cBF degeneration and cognitive decline (rcBF‐MoCA = 0.30, P < 0.001). Interestingly, both longitudinal cBF degeneration and its association with cortical thinning were largely independent of amyloid‐β status.Conclusions: cBF degeneration in PD is linked to parallel thinning of cortical target areas, which mediate the effect on cognitive decline. These associations are independent of amyloid‐β status, indicating that they reflect proper features of PD pathophysiology. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 13 March 2023
- Published by Wiley in Movement Disorders
- Vol. 38 (5) , 755-763
Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease
Background: Peripheral inflammatory immune responses are suggested to play a major role in dopaminergic degeneration in Parkinson's disease (PD). The neutrophil‐to‐lymphocyte ratio (NLR) is a well‐established biomarker of systemic inflammation in PD. Degeneration of the nigrostriatal dopaminergic system can be assessed in vivo using [123I]FP‐CIT single photon emission computed tomography imaging of striatal dopamine transporter (DAT) density.Objectives: To assess the relationship between the peripheral immune profile (NLR, lymphocytes, and neutrophils) and striatal DAT density in patients with PD.Methods: We assessed clinical features, the peripheral immune profile, and striatal [123I]FP‐CIT DAT binding levels of 211 patients with PD (primary‐cohort). Covariate‐controlled associations between the immune response and striatal DAT levels were assessed using linear regression analyses. For replication purposes, we also studied a separate cohort of 344 de novo patients with PD enrolled in the Parkinson's Progression Markers Initiative (PPMI‐cohort).Results: A higher NLR was significantly associated with lower DAT levels in the caudate (primary‐cohort: β = −0.01, p < 0.001; PPMI‐cohort: β = −0.05, p = 0.05) and the putamen (primary‐cohort: β = −0.05, p = 0.02; PPMI‐cohort: β = −0.06, p = 0.02). Intriguingly, a lower lymphocyte count was significantly associated with lower DAT levels in both the caudate (primary‐cohort: β = +0.09, p < 0.05; PPMI‐cohort: β = +0.11, p = 0.02) and the putamen (primary‐cohort: β = +0.09, p < 0.05, PPMI‐cohort: β = +0.14, p = 0.01), but an association with the neutrophil count was not consistently observed (caudate; primary‐cohort: β = −0.05, p = 0.02; PPMI‐cohort: β = 0, p = 0.94; putamen; primary‐cohort: β = −0.04, p = 0.08; PPMI‐cohort: β = −0.01, p = 0.73).Conclusions: Our findings across two independent cohorts suggest a relationship between systemic inflammation and dopaminergic degeneration in patients with PD. This relationship was mainly driven by the lymphocyte count. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 13 March 2023
- Published by Wiley in Movement Disorders
- Vol. 38 (5) , 755-763
Open AccessPeripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease
Background: Peripheral inflammatory immune responses are suggested to play a major role in dopaminergic degeneration in Parkinson's disease (PD). The neutrophil‐to‐lymphocyte ratio (NLR) is a well‐established biomarker of systemic inflammation in PD. Degeneration of the nigrostriatal dopaminergic system can be assessed in vivo using [123I]FP‐CIT single photon emission computed tomography imaging of striatal dopamine transporter (DAT) density.Objectives: To assess the relationship between the peripheral immune profile (NLR, lymphocytes, and neutrophils) and striatal DAT density in patients with PD.Methods: We assessed clinical features, the peripheral immune profile, and striatal [123I]FP‐CIT DAT binding levels of 211 patients with PD (primary‐cohort). Covariate‐controlled associations between the immune response and striatal DAT levels were assessed using linear regression analyses. For replication purposes, we also studied a separate cohort of 344 de novo patients with PD enrolled in the Parkinson's Progression Markers Initiative (PPMI‐cohort).Results: A higher NLR was significantly associated with lower DAT levels in the caudate (primary‐cohort: β = −0.01, p < 0.001; PPMI‐cohort: β = −0.05, p = 0.05) and the putamen (primary‐cohort: β = −0.05, p = 0.02; PPMI‐cohort: β = −0.06, p = 0.02). Intriguingly, a lower lymphocyte count was significantly associated with lower DAT levels in both the caudate (primary‐cohort: β = +0.09, p < 0.05; PPMI‐cohort: β = +0.11, p = 0.02) and the putamen (primary‐cohort: β = +0.09, p < 0.05, PPMI‐cohort: β = +0.14, p = 0.01), but an association with the neutrophil count was not consistently observed (caudate; primary‐cohort: β = −0.05, p = 0.02; PPMI‐cohort: β = 0, p = 0.94; putamen; primary‐cohort: β = −0.04, p = 0.08; PPMI‐cohort: β = −0.01, p = 0.73).Conclusions: Our findings across two independent cohorts suggest a relationship between systemic inflammation and dopaminergic degeneration in patients with PD. This relationship was mainly driven by the lymphocyte count. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.